Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

PIRAMAL PHARMA LIMITED Call Transcript 2024

Oct 24, 2024

59525_rns_2024-10-24_f8ddc27f-6edd-47f9-89b1-c5a5cdf46519.pdf

Call Transcript

Open in viewer

Opens in your device viewer

==> picture [145 x 60] intentionally omitted <==

24[th] October, 2024

BSE Limited P.J. Towers, Dalal Street, Fort, Mumbai- 400 001 BSE scrip code: 543635

National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex, Bandra (East), Mumbai – 400 051 NSE symbol: PPLPHARMA

Sub: Audio Recording of Conference Call on the Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30[th] September, 2024

Dear Sir / Madam,

In continuation of our letter dated 14[th] October, 2024 and pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of the conference call held on 24[th] October, 2024 on the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended 30[th] September, 2024 is available on the Company’s website at - https://www.piramalpharma.com/financial reports

Kindly take the above on record.

Thanking you,

Yours truly,

For Piramal Pharma Limited

Digitally signed TANYA by TANYA SANISH Date: 2024.10.24 SANISH 18:21:40 +05'30' Tanya Sanish Company Secretary

Piramal Pharma Limited

CIN: L24297MH2020PLC338592 Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India T: +91 22 3802 3000 / 4000; Email : [email protected]

piramalpharma.com